Insmed

Insmed Debt

The Debt of Insmed (INSM) as of Oct 28, 2026 is 560.23 M USD. In the previous year, Debt was 1.29 B USD — a change of -56.62% (lower).

Debt

560.23 MUSD

YoY

-56.62%

Last updated:

In 2025, Insmed's total debt was 560.23 M USD, a -56.62% change from the 1.29 B USD total debt recorded in the previous year.

The Insmed Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
316.60 M USD
Jan 1, 2019
356.70 M USD
Jan 1, 2020
372.10 M USD
Jan 1, 2021
581.30 M USD
Jan 1, 2022
1.16 B USD
Jan 1, 2023
1.34 B USD
Jan 1, 2024
1.29 B USD
Jan 1, 2025
560.23 M USD
The Insmed Debt history
YEARDebtYoY
560.23 MUSD-56.62%
1.29 BUSD-3.62%
1.34 BUSD+15.91%
1.16 BUSD+98.88%
581.30 MUSD+56.22%
372.10 MUSD+4.32%
356.70 MUSD+12.67%
316.60 MUSD+469.42%
55.60 MUSD+1.46%
54.80 MUSD+118.33%
25.10 MUSD+0.80%
24.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Debt Details

Understanding Insmed's Debt Structure

Insmed's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Insmed's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Insmed’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Insmed’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Insmed stock

Debt of Insmed is 560.23 M USD in 2025.

Debt of Insmed changed from 1.29 B USD to 560.23 M USD, representing a -56.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Insmed since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Insmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Insmed

All Key Metrics — Insmed